Results of the study were presented at ENDO 2017, the Endocrine Society’s annual meeting in Orlando, Florida. In the study, postmenopausal women with low bone mass were randomized to receive either 24 months of placebo or 24 months of Evenity. In the following 12 months, these patients were re-randomized to receive either denosumab (Prolia) or placebo. For the last 12 months of the study, all patients received Evenity for 12 months.
Results indicated that patients who received Evenity followed by placebo saw positive reactions when going back on Evenity in the last 12 months. Patients who went from denosumab to Evenity also saw positive reactions.
"Since osteoporosis is a chronic condition, which may lead to debilitating fractures, the option of providing a second course of bone-building therapy may benefit some patients with severe osteoporosis," Dr. David L. Kendler, a lead study investigator, said in a statement. "This latest study is important as it shows that the safety and efficacy of romosozumab extends from initial use to a second course of treatment."
Alerts Sign-up